Hims & Hers Health (HIMS) Share-based Compensation (2020 - 2026)
Hims & Hers Health's (HIMS) quarterly Share-based Compensation came in at $36.9 million in Q1 2026, up 48.29% year-on-year from $24.9 million in Q1 2025, and up 6.88% quarter-over-quarter from $34.5 million in Q4 2025.
Hims & Hers Health (HIMS) Share-based Compensation (2020 - 2026) Analysis & Trends
Hims & Hers Health has disclosed Share-based Compensation across 7 years of filings, most recently posting $36.9 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $36.9 million, up 48.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $147.2 million (up 50.03% YoY), and the FY2025 annual result was $135.2 million, up 46.49% from the prior year.
- Share-based Compensation came in at $36.9 million for Q1 2026 at Hims & Hers Health, up from $34.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $40.2 million in Q3 2025 to a low of $8.9 million in Q1 2022.
- The 5-year median for Share-based Compensation is $19.0 million (2024), against an average of $22.0 million.
- Across the five-year window, Share-based Compensation sank 74.13% in 2022 and surged 61.34% in 2025, its largest moves.
- Hims & Hers Health's Share-based Compensation stood at $12.4 million in 2022, then surged by 44.06% to $17.8 million in 2023, then surged by 36.86% to $24.3 million in 2024, then surged by 41.64% to $34.5 million in 2025, then increased by 6.88% to $36.9 million in 2026.
- The last three Share-based Compensation figures came in at $36.9 million (Q1 2026), $34.5 million (Q4 2025), and $40.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 16.04 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 36.86 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 9.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.86 Mn |
| Mar 31, 2026 | 36.86 Mn |
| Dec 31, 2025 | 34.49 Mn |
| Dec 31, 2025 | 34.49 Mn |
| Sep 30, 2025 | 40.17 Mn |
| Sep 30, 2025 | 40.17 Mn |
| Jun 30, 2025 | 35.73 Mn |
| Jun 30, 2025 | 35.73 Mn |
| Mar 31, 2025 | 24.86 Mn |
| Mar 31, 2025 | 24.86 Mn |
| Dec 31, 2024 | 24.35 Mn |
| Dec 31, 2024 | 24.35 Mn |
| Sep 30, 2024 | 24.90 Mn |
| Sep 30, 2024 | 24.90 Mn |
| Jun 30, 2024 | 24.04 Mn |
| Jun 30, 2024 | 24.04 Mn |
| Mar 31, 2024 | 19.03 Mn |
| Mar 31, 2024 | 19.03 Mn |
| Dec 31, 2023 | 17.79 Mn |
| Dec 31, 2023 | 17.79 Mn |